Preferred Label : Bevacizumab;
NCIt synonyms : Anti-VEGF rhuMAb; Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular
Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light
Chain, Dimer; Anti-VEGF Humanized Monoclonal Antibody; Recombinant Humanized Anti-VEGF Monoclonal Antibody; rhuMab-VEGF; Bevacizumab Biosimilar CBT 124; Bevacizumab Biosimilar BEVZ92; Bevacizumab Biosimilar BI 695502; Bevacizumab Biosimilar FKB238; Bevacizumab Biosimilar HD204; Bevacizumab Biosimilar QL 1101; Bevacizumab Biosimilar MIL60; Bevacizumab Biosimilar HLX04; Bevacizumab Biosimilar IBI305; Bevacizumab Biosimilar SCT501; Bevacizumab Biosimilar LY01008; Bevacizumab awwb; Bevacizumab Biosimilar RPH-001; BP102 Biosimilar; Bevacizumab Biosimilar CT-P16; Bevacizumab Biosimilar Zirabev; Bevacizumab Biosimilar Mvasi; Bevacizumab Biosimilar GB-222; Bevacizumab Biosimilar MYL-1402O; Bevacizumab Biosimilar ABP 215; Anti-VEGF Monoclonal Antibody SIBP04; Bevacizumab Biosimilar QL1101; Bevacizumab-adcd; BAT1706 Biosimilar; Bevacizumab Biosimilar BAT1706;
NCIt related terms : Bevacizumab-awwb; Bevacizumab-bvzr; Anti-VEGF; Avastin;
NCIt definition : A recombinant humanized monoclonal antibody directed against the vascular endothelial
growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits
VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood
vessels.;
Alternative definition : NCI-GLOSS: A drug used to treat several types of cancer, including certain types of
colorectal, lung, breast, and kidney cancers and glioblastoma. It is also being studied
in the treatment of other types of cancer. Avastin binds to vascular endothelial growth
factor (VEGF) and may prevent the growth of new blood vessels that tumors need to
grow. It is a type of antiangiogenesis agent and a type of monoclonal antibody.;
UNII : 2S9ZZM9Q9V;
CAS number : 216974-75-3; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 216974-75-3
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Avastin; Zirabev; Mvasi; Vegzelma;
Molecule name : HD204; SCT501; BP102; MYL-1402O; ABP 215; SIBP 04; SIBP-04; QL1101; BAT 1706; CT-P16; BAT-1706;
NSC code : 704865;
Codes from synonyms : NSC0704865; CDR0000367431; CDR0000046115; 27957; 13334; 67; 68;
Origin ID : C2039;
UMLS CUI : C0796392;
Automatic exact mappings (from CISMeF team)
- CISMeF manual mappings
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_affects_gene_product
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
https://pgtmsite.files.wordpress.com/2024/01/bevacizumab-cancer-du-col_es-public_final-post-tdesc-24mar2017.pdf
2017
Canada
drug information
uterine cervical neoplasms
Bevacizumab
cancer of the uterine cervix
malignant neoplasm cervix
Cervical Cancer pT1a1 TNM Finding v8
neoplasm, malignant
bevacizumab
avastin
Cervical Carcinoma
Cancer Therapeutic Procedure
Bevacizumab
---
https://pgtmsite.files.wordpress.com/2024/01/bevacizumab_colonmetastatique_pgtm_20071213.pdf
2007
Canada
drug information
Bevacizumab
Colon Carcinoma
colonic neoplasms
bevacizumab
neoplasm, malignant
cancer of colon
Metastatic Malignant Neoplasm
Bevacizumab
large intestine, nos
---
https://pgtmsite.files.wordpress.com/2024/01/bevacizumab_dmla_pgtm_20070201.pdf
2007
Canada
drug information
Bevacizumab
Macular Degeneration
degeneration, nos
macular degeneration
bevacizumab
macular degeneration
Bevacizumab
macule, nos
---
